Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.31 |
| ▸ | CPT2 | P23786 | 2/20 | 0.30 |
| ▸ | CPT1A | P50416 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21470503 | 0.91 | NR1H2 (0.37) | HRH3 | |
| SCHEMBL23326762 | 0.78 | F10 (0.32) | HRH3CHRM4CPT2CPT1A | |
| SCHEMBL23327012 | 0.73 | F10 (0.36) | HRH3CHRM4CYP4F2CYP4A11 | |
| SCHEMBL23326985 | 0.72 | KIT (0.42) | — | |
| SCHEMBL21470499 | 0.70 | NR1H2 (0.41) | HRH3CHRM4 | |
| SCHEMBL21470821 | 0.66 | NR1H2 (0.44) | — | |
| SCHEMBL21470893 | 0.65 | MKNK1 (0.43) | — | |
| SCHEMBL21470892 | 0.65 | FGFR4 (0.47) | — | |
| SCHEMBL21470706 | 0.65 | NR1H2 (0.42) | — | |
| SCHEMBL21470820 | 0.64 | NR1H2 (0.42) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | ROCK2 944/4885HRH3 334/4885CHRM4 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.